The STRO-004 early clinical data is the primary catalyst, validating the platform and de-risking the pipeline. Traders should monitor for the next STRO-004 update in 1H 2027 and the initiation of the STRO-006 Phase 1 trial in Q3 2026. The cash runway into Q2 2028 removes near-term financing risk.
Price Chart
Executive Summary
Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS -$2.33 vs -$1.35 YoY), a significant decline from the prior year which included a large milestone payment. However, the stock catalyst is the early Phase 1 data for STRO-004, showing confirmed and unconfirmed partial responses in heavily pretreated pancreatic, head and neck, and NSCLC patients with a favorable tolerability profile and differentiated PK. The clinical validation of the platform is the primary driver, outweighing the weak financial quarter for a clinical-stage biotech.
Key Financial Metrics
Key Facts
- Revenue was $9.8M for Q2 2026, down from $63.7M in Q2 2025, with the 2026 amount related principally to the Astellas collaboration.
- Net loss was $38.5M (EPS -$2.33) vs $11.5M (EPS -$1.35) in Q2 2025.
- Cash, cash equivalents and marketable securities were $164.3M as of June 30, 2026, expected to support operations into at least Q2 2028.
- STRO-004 Phase 1 data shows confirmed and ongoing unconfirmed partial responses in pancreatic, head and neck, and NSCLC at dose levels 3-4 mg/kg.
- Favorable tolerability profile with mostly low-grade AEs; discontinuation rate due to AEs was 6%.
- STRO-004 has a half-life of nearly seven days, preserving 98% DAR8 configuration with low free payload.
- STRO-006 on track to enter the clinic in Q3 2026; STRO-227 IND submission expected in 2026.
- Second Astellas dual-payload iADC program expected to enter the clinic in 2H 2026.
Financial Impact
Revenue declined $53.9M YoY due to the absence of a large milestone payment; net loss widened by $27.0M. Cash burn of ~$38.3M in Q2.
Risk Factors
- STRO-004 data is early (Phase 1 dose escalation, n=49) with limited follow-up; responses are not yet durable.
- Revenue is highly dependent on collaboration milestones, which are unpredictable.
- Significant stockholders' deficit of $103.3M and deferred royalty obligation of $239.1M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-345733 |
| Document: stro-20260812.htm | 0001193125-26-345733 |
| Document: stro-ex99_2.htm | 0001193125-26-345733 |
| Document: 0001193125-26-345733-index-headers.html | 0001193125-26-345733 |
| Document: 0001193125-26-345733-index.html | 0001193125-26-345733 |
| Document: 0001193125-26-345733.txt | 0001193125-26-345733 |
| 8-K Data (Synthetic) | 0001193125-26-345733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.32 (−28.08%) |
Aug 12, 2026 7w ago | Press Release | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.32 (−28.08%) |
Apr 22, 2026 23w ago | DEFA14A | $34.83 $31.13 | ▼ −10.62% | ▼ −15.26% | $15.32 (−56.01%) |
Apr 19, 2026 23w ago | Press Release | $34.58 $34.48 | ▼ −0.29% | ▼ −4.49% | $15.32 (−55.70%) |
Mar 23, 2026 27w ago | S-3 | $23.57 $35.53 | ▼ −50.74% | ▼ −41.84% | $15.32 (+35.00%) |
Mar 23, 2026 27w ago | Press Release | $23.57 $35.53 | ▲ +50.74% | ▲ +41.84% | $15.32 (−35.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access